Derivation and Validation of a Risk Prediction Model for Vancomycin-Associated Acute Kidney Injury in Chinese Population

References

• Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2010;51(Suppl 2):S183–S197. doi:10.1086/653519
   PubMed Web of Science ®Google Scholar
• Elyasi S, Khalili H, Dashti-Khavidaki S, et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012;68:1243–1255. doi:10.1007/s00228-012-1259-9
   PubMed Web of Science ®Google Scholar
• Prendecki M, Blacker E, Sadeghi-Alavijeh O, et al. Improving outcomes in patients with acute kidney injury: the impact of hospital based automated AKI alerts. Postgrad Med J. 2016;92:9–13. doi:10.1136/postgradmedj-2015-133496
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–e55.
   PubMed Web of Science ®Google Scholar
• Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Ch. 2011;55:5475–5479.
   PubMed Web of Science ®Google Scholar
• Park SJ, Lim NR, Park HJ, et al. Evaluation of risk factors for vancomycin-induced nephrotoxicity. Int J Clin Pharm. 2018;40:1328–1334. doi:10.1007/s11096-018-0634-8
   PubMed Web of Science ®Google Scholar
• Ye ZK, Chen YL, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese pharmacological society. J Antimicrob Chemother. 2016;71:3020–3025. doi:10.1093/jac/dkw254
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Ph. 2020;77(11):835–864.
   PubMed Web of Science ®Google Scholar
• Inage S, Nakamura S, Isoe Y, et al. Acute kidney injury in non-intensive care unit and intensive care unit patients treated with vancomycin and piperacillin-tazobactam. J Nippon Med Sch. 2019:JNMS-2020_87.
   PubMed Web of Science ®Google Scholar
• Navalkele B, Pogue JM, Karino S, et al. Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to those on vancomycin and cefepime. Clin Infect Dis. 2017;64:116–123. doi:10.1093/cid/ciw709
   PubMed Web of Science ®Google Scholar
• Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025–1034. doi:10.1016/S0140-6736(17)30397-5
   PubMed Web of Science ®Google Scholar
• Gholipour K, Asghari-Jafarabadi M, Iezadi S, et al. Modelling the prevalence of diabetes mellitus risk factors based on artificial neural network and multiple regression. East Mediterr Health J. 2018;24(08):770–777. doi:10.26719/emhj.18.012
   PubMed Web of Science ®Google Scholar
• Cintolo-Gonzalez JA, Braun D, Blackford AL, et al. Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. Breast Cancer Res Treat. 2017;164:263–284. doi:10.1007/s10549-017-4247-z
   PubMed Web of Science ®Google Scholar
• Pan C, Wen A, Li X, et al. Development and validation of a risk prediction model of vancomycin-associated nephrotoxicity in elderly patients: a pilot study. Clin Transl Sci. 2019.
   Web of Science ®Google Scholar
• Imai S, Yamada T, Kasashi K, et al. Construction of a risk prediction model of vancomycin-associated nephrotoxicity to be used at the time of initial therapeutic drug monitoring: a data mining analysis using a decision tree model. J Eval Clin Pract. 2019;25:163–170. doi:10.1111/jep.13039
   PubMed Web of Science ®Google Scholar
• Imai S, Yamada T, Kasashi K, et al. Usefulness of a decision tree model for the analysis of adverse drug reactions: evaluation of a risk prediction model of vancomycin-associated nephrotoxicity constructed using a data mining procedure. J Eval Clin Pract. 2017;23:1240–1246. doi:10.1111/jep.12767
   PubMed Web of Science ®Google Scholar
• Collins GS, Reitsma JB, Altman DG, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med. 2015;162:55–63. doi:10.7326/M14-0697
   PubMed Web of Science ®Google Scholar
• Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63:713–735. doi:10.1053/j.ajkd.2014.01.416
   PubMed Web of Science ®Google Scholar
• Fluss R, Faraggi D, Reiser B. Estimation of the Youden index and its associated cutoff point. Biom J. 2005;47:458–472. doi:10.1002/bimj.200410135
   PubMed Web of Science ®Google Scholar
• Wang Y, Bellomo R. Cardiac surgery-associated acute kidney injury: risk factors, pathophysiology and treatment. Nat Rev Nephrol. 2017;13:697–711. doi:10.1038/nrneph.2017.119
   PubMed Web of Science ®Google Scholar
• Jeon N, Staley B, Klinker KP, et al. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function. Int J Antimicrob Ag. 2017;50:63–67.
   PubMed Web of Science ®Google Scholar
• Dong M-H, Wang JW, Wu Y, et al. Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China. Int J Infect Dis. 2015;37:125–128. doi:10.1016/j.ijid.2015.06.025
   PubMed Web of Science ®Google Scholar
• Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014;34:670–676. doi:10.1002/phar.1442
   PubMed Web of Science ®Google Scholar
• Perazella MA. Drug-induced acute kidney injury: diverse mechanisms of tubular injury. Curr Opin Crit Care. 2019;25:550–557. doi:10.1097/MCC.0000000000000653
   PubMed Web of Science ®Google Scholar
• Huang M, Wu H, Zhou J, et al. Efficacy of vancomycin on gram-positive bacterial infection in elderly critical patients and risk factors associated with nephrotoxicity. Arch Iran Med. 2018;21:349–355.
   PubMed Web of Science ®Google Scholar
• Peyko V, Smalley S, Cohen H. Prospective comparison of acute kidney injury during treatment with the combination of piperacillin-tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin. J Pharm Pract. 2017;30(2):209–213. doi:10.1177/0897190016628960
   PubMedGoogle Scholar
• Chen X-Y, Xu R-X, Zhou X, et al. Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(11):2019–2026. doi:10.1007/s11255-018-1870-5
   PubMed Web of Science ®Google Scholar
• Hammond DA, Smith MN, Li C, et al. Systematic review and meta-analysis of acute kidney injury Associated with concomitant vancomycin and piperacillin/tazobactam. Clin Infect Dis. 2017;64(5):666–674. doi:10.1093/cid/ciw811
   PubMed Web of Science ®Google Scholar
• Bellos I, Karageorgiou V, Pergialiotis V, et al. Acute kidney injury following the concurrent administration of antipseudomonal beta-lactams and vancomycin: a network meta-analysis. Clin Microbiol Infect. 2020;20:30164–30166.
   Google Scholar